Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRG2 | P18507 | 4/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 4/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.33 |
| ▸ | GABRA6 | Q16445 | 4/20 | 0.33 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.33 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.33 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.32 |
| ▸ | TYMS | P04818 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10234322 | 1.00 | GABRG2 (0.33) | GABRG2GABRB3GABRA5GABRA6GABRA4 | |
| SCHEMBL12295799 | 0.90 | GABRA5 (0.38) | GABRG2GABRB3GABRA5GABRA6GABRA4 | |
| SCHEMBL12328158 | 0.89 | GPR119 (0.31) | — | |
| SCHEMBL12373650 | 0.87 | HCRTR1 (0.33) | — | |
| SCHEMBL10202472 | 0.87 | HCRTR1 (0.33) | — | |
| SCHEMBL13746544 | 0.87 | TYMS (0.35) | GABRG2GABRB3GABRA5GABRA6GABRA4 | |
| SCHEMBL883262 | 0.87 | TYMS (0.35) | GABRG2GABRB3GABRA5GABRA6GABRA4 | |
| SCHEMBL2065597 | 0.87 | TYMS (0.35) | GABRG2GABRB3GABRA5GABRA6GABRA4 | |
| SCHEMBL2065596 | 0.87 | TYMS (0.35) | GABRG2GABRB3GABRA5GABRA6GABRA4 | |
| SCHEMBL10234317 | 0.86 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8796466-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-08-05 | — | — | US | disclosed |
| US-20110237636-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-09-29 | — | — | US | disclosed |
| US-20110237636-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-09-29 | — | — | US | disclosed |
| US-20110077280-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237636-A1 | Hepatitis C Virus Inhibitors | HAVCR2, EIF2AK2, MAVS | GABRG2 3606/4885GABRB3 3509/4885GABRA5 4319/4885 |
| US-20110077280-A1 | Hepatitis C Virus Inhibitors | HAVCR2, EIF2AK2, MAVS | GABRG2 3606/4885GABRB3 3509/4885GABRA5 4319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.